Immunoglobulins
US7858753B2 · kind B2 · utility
4Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 29, 2005 |
| Grant date | Dec 28, 2010 |
| Priority date | — |
| Expiry date | Sep 30, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.